Sandoz starts with Zessly in Germany

Germany has become the launch market for Sandoz’Zessly (infliximab) biosimilar after the company’s Hexal affiliate introduced the rival to Merck Sharp & Dohme’s (MSD’s) Remicade on 15 November. Launch list prices for Zessly 100mg powder for concentrate range from €705.29 (US$804.00) for one 100mg vial to €3,467.28 for a pack of five, representing a modest 5% discount to MSD’s list price for Remicade.